Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: A prospective study

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3614-3620

  Van Houten, Viola M M ^a   Leemans, C René ^a   Kummer, J Alain ^a   Dijkstra, Janny ^a   Kuik, Dirk J ^a   Van Den Brekel, Michiel W M ^a   Snow, Gordon B ^a   Brakenhoff, Ruud H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; COHORT ANALYSIS; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DNA; FEMALE; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; RECURRENCE; RISK; RNA; TIME FACTORS;

EID: 2542570373     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0631     Document Type: Article

References (16)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer (Phila) 1994;73:187-90.
3. Van Houten VMM, Tabor MP, van den Brekel MWM, et al. Mutated p53 as molecular marker for the diagnosis of head and neck cancer. J Pathol 2002;198:476-86.
4. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-30.
5. Tabor MP, Brakenhoff RH, van Houten VMM, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001;7:1523-32.
6. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science (Wash DC) 1991;253:49-53.
8. Tabor MP, van Houten VMM, Kummer JA, et al. Genetic differences between primary head and neck tumors and metastases depend on mutational status of the p53 gene. Genes Chromosomes Cancer 2002; 33:168-77.
9. Sidransky D, von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science (Wash DC) 1991;252:706-9.
10. Van Houten VMM, Tabor MP, van den Brekel MWM, et al. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 2000;6:3803-16.
11. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995;332:429-35.
12. Partridge M, Li SR, Pateromichelakis S, et al. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res 2000;6:2718-25.
13. Dixon WJ. BMDP statistical software manual to accompany the 7.0 software release. Los Angeles, CA: University of California Press; 1992.
14. Nieuwenhuis EJC, Jaspers EHJ, Castelijns JA, et al. Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates Clin Cancer Res 2003;9:755-61.
15. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
16. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.